STRATA Skin Sciences to Report Fourth Quarter and Year End 2024 Financial Results on March 27, 2025 and Provide Corporate Update
STRATA Skin Sciences (NASDAQ: SSKN), a medical technology company focused on dermatologic treatments, has scheduled its Fourth Quarter and Year End 2024 financial results announcement for March 27, 2025 after market close.
The company will host a conference call at 4:30 p.m. ET on the same day, featuring management's remarks and a Q&A session. Investors can access the call through domestic (1-844-481-2523) or international (1-412-317-0552) dial-in numbers.
A webcast replay will be available until September 21, 2025, while telephonic replay access will be available until April 3, 2025 using the code 8210574.
STRATA Skin Sciences (NASDAQ: SSKN), un'azienda di tecnologia medica focalizzata sui trattamenti dermatologici, ha programmato l'annuncio dei risultati finanziari del Quarto Trimestre e Fine Anno 2024 per il 27 marzo 2025 dopo la chiusura del mercato.
L'azienda ospiterà una conferenza telefonica alle 16:30 ET lo stesso giorno, con le osservazioni della direzione e una sessione di domande e risposte. Gli investitori possono accedere alla chiamata tramite i numeri di accesso nazionali (1-844-481-2523) o internazionali (1-412-317-0552).
Una registrazione del webcast sarà disponibile fino al 21 settembre 2025, mentre l'accesso alla registrazione telefonica sarà disponibile fino al 3 aprile 2025 utilizzando il codice 8210574.
STRATA Skin Sciences (NASDAQ: SSKN), una empresa de tecnología médica centrada en tratamientos dermatológicos, ha programado el anuncio de sus resultados financieros del Cuarto Trimestre y Fin de Año 2024 para el 27 de marzo de 2025 después del cierre del mercado.
La empresa llevará a cabo una conferencia telefónica a las 4:30 p.m. ET el mismo día, que incluirá comentarios de la dirección y una sesión de preguntas y respuestas. Los inversores pueden acceder a la llamada a través de números de marcación nacionales (1-844-481-2523) o internacionales (1-412-317-0552).
Una repetición de la transmisión web estará disponible hasta el 21 de septiembre de 2025, mientras que el acceso a la repetición telefónica estará disponible hasta el 3 de abril de 2025 utilizando el código 8210574.
STRATA Skin Sciences (NASDAQ: SSKN), 피부 치료에 중점을 둔 의료 기술 회사가 2024년 4분기 및 연말 재무 결과 발표를 2025년 3월 27일 시장 종료 후로 예정했습니다.
회사는 같은 날 오후 4시 30분 ET에 경영진의 발언과 Q&A 세션을 포함한 전화 회의를 개최할 것입니다. 투자자는 국내 전화번호(1-844-481-2523) 또는 국제 전화번호(1-412-317-0552)를 통해 통화에 접속할 수 있습니다.
웹캐스트 재생은 2025년 9월 21일까지 이용 가능하며, 전화 재생 접근은 2025년 4월 3일까지 코드 8210574를 사용하여 가능합니다.
STRATA Skin Sciences (NASDAQ: SSKN), une entreprise de technologie médicale spécialisée dans les traitements dermatologiques, a prévu l'annonce de ses résultats financiers pour le Quatrième Trimestre et Fin d'Année 2024 pour le 27 mars 2025 après la fermeture du marché.
L'entreprise organisera une conférence téléphonique à 16h30 ET le même jour, avec les remarques de la direction et une session de questions-réponses. Les investisseurs peuvent accéder à l'appel via les numéros d'appel nationaux (1-844-481-2523) ou internationaux (1-412-317-0552).
Une rediffusion du webinaire sera disponible jusqu'au 21 septembre 2025, tandis que l'accès à la rediffusion téléphonique sera disponible jusqu'au 3 avril 2025 en utilisant le code 8210574.
STRATA Skin Sciences (NASDAQ: SSKN), ein Medizintechnikunternehmen, das sich auf dermatologische Behandlungen spezialisiert hat, hat die Bekanntgabe seiner finanziellen Ergebnisse für das 4. Quartal und das Geschäftsjahr 2024 für den 27. März 2025 nach Marktschluss angesetzt.
Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz abhalten, in der die Anmerkungen des Managements und eine Q&A-Session vorgestellt werden. Investoren können über die nationalen (1-844-481-2523) oder internationalen (1-412-317-0552) Telefonnummern an dem Anruf teilnehmen.
Eine Aufzeichnung des Webcasts wird bis zum 21. September 2025 verfügbar sein, während der telefonische Zugriff auf die Aufzeichnung bis zum 3. April 2025 mit dem Code 8210574 verfügbar ist.
- None.
- None.
HORSHAM, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report fourth quarter and year end 2024 financial results on Thursday, March 27, 2025 after the market close.
STRATA management will host a conference call at 4:30 p.m. ET on Thursday, March 27, 2025 to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question-and-answer session.
To listen to the conference call, interested parties within the U.S. should dial 1-844-481-2523 (domestic) or 1-412-317-0552 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the STRATA Skin Sciences, Inc. conference call.
The conference call will also be available through a live webcast that can be accessed at STRATA Skin Sciences YE24 Earnings Webcast.
A telephonic replay of the call will be available until April 3, 2025 by dialing 1-877-344-7529 (or 1-412-317-0088 for international toll callers) and using replay access code 8210574. To access the replay using an international dial-in number, please see here.
A webcast earnings call replay will be available approximately one hour after the live call and remain accessible until September 21, 2025.
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClear®X Acne Therapy System.
STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.
Safe Harbor
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and sell products recently acquired or to be developed in the future, the Company’s ability to develop social media marketing campaigns, direct to consumer marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.
Investor Contact:
CORE IR
516-222-2560
IR@strataskin.com
FAQ
When will STRATA Skin Sciences (SSKN) release Q4 and Year End 2024 earnings?
How can investors join SSKN's Q4 2024 earnings call?
How long will SSKN's Q4 2024 earnings call replay be available?
What is the replay access code for SSKN's Q4 2024 earnings call?
